banner轮播的第一个标题

About Us

WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. 

WuXi STA oligonucleotide platform provides comprehensive CRDMO (Contract Research, Development and Manufacturing Organization) service from drug discovery to commercial manufacturing, combining traditional CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) services under one roof.  

Our chemistry platform includes synthesis of novel monomers and ligands, oligonucleotides, and complex conjugates. Our state-of-the-art facilities support oligo API development and manufacturing at any scale from nmol to mol. Our CMC platform includes API, drug product, analytical, and CMC writing providing a one-stop solution for oligo therapeutic development.


  • Oligonucleotide CRDMO chemistry platform

    From Discovery to Development and Commercial Manufacturing

    • Monomer/Ligand

      Novel Amidite 

      GalNAc

      Nucleoside/Nucleotide

      mRNA NTP/Capping Reagent

    • Oligo (from nmol to mol)

      DNA

      ASO

      siRNA

      Aptamer

      PMO, etc.

    • Conjugate

      PPMO

      Oligo-GalNAc

      Oligo-Toxin

      Oligo-Antibody

      Oligo-Peptide, etc.

  • Oligonucleotide CMC platform

    • PRE-CLINICAL

    • PHASE I

    • PHASE II

    • PHASE III

    • COMMERCIAL

    • API

      PROCESS R&D AND MANUFACTURING

      (monomer ligand oligo conjugate)

    • Drug product

      PRE-FORMULATION, FORMULATION DEVELOPMENT & MANUFACTURING

      (injectable, LNP delivery technology)

    • Analytical

      ANALYTICAL DEVELOPMENT, QUALITY CONTROL AND STABILITY STUDIES

    • Regulatory CMC

      CMC DOSSIER PREPARATION TO SUPPORT GLOBAL REGULATORY FILING

  • Oligo CRDMO CDMO CMO
  • Oligo CMC | API | product drug

Why WuXi STA?

  • Scalability

    From discovery to development and commercialization all within WuXi STA with readily available large R&D and manufacturing capacity


  • Conjugation Chemistry

    Seamless collaboration among oligo, peptide and small molecule teams

  • New Technology

    Access to new technologies including liquid phase synthesis, biocatalysis, thin film evaporation, spray dried dispersion and API isolation in solution

sy_imgxz1.svg
  • Global Quality Standard

    One quality system across all sites approved by major regulatory agencies around the world

  • Comprehensive Analytical Platform

    Method development and validation, IPC and release testing, characterization, stability

  • Integrated CMC

    API process R&D and manufacturing, formulation development and manufacturing, analytical, CMC dossier preparation and clinical supply services